Eli Lilly's dulaglutide, a GLP-1 receptor agonist, is being evaluated for safety in a diverse population of patients with Type 2 Diabetes Mellitus (T2DM) in India. Given the increasing prevalence of diabetes in India, this study addresses a significant market need. The results could reinforce dulaglutide's position in the competitive landscape against other GLP-1 receptor agonists and oral antihyperglycemic agents. Successful outcomes may enhance market penetration and support further regulatory approvals in the region. Additionally, the study's completion and subsequent data publication will be critical for Eli Lilly's ongoing commercial strategy and investor confidence.